This study assessed the long-term economic implications of a national program to vaccinate all adults treated at sexually transmitted disease (STD) clinics in a single year.
Methods.
A model was developed to track the long-term disease outcomes and costs among a hypothetical cohort of 2 million STD clinic clients accessing services in one year, using data from published sources and demonstration projects at STD clinics in San Diego (California), Illinois, and Denver (Colorado). The model estimated net economic benefits of a routine hepatitis B vaccination policy at STD clinics nationwide compared with no vaccination.
Results.
Without a vaccination program, an estimated 237,021 new hepatitis B virus (HBV) infections would occur over the lifetimes of the 2 million STD clinic clients seen in a single year. HBV-related medical costs and productivity losses would be $1.6 billion. In a national program for routine vaccination at STD clinics, 1.3 million adults would be expected to receive at least one vaccine dose, and an estimated 45% of the new HBV infections expected without vaccination would be prevented. The vaccination program would cost $138 million, HBV infections occurring despite the program would cost $878 million, and clients' time and travel would cost $45 million. The net economic benefit (savings) of routine vaccination would be $526 million. If the indirect costs of lost productivity due to HBV infection are not considered, routine vaccination would have a net cost of $28 million.
Conclusions.
Estimates from this model suggest a national program for routine hepatitis B vaccination of adults at STD clinics would be a cost saving to society.
GoldsteinSTAlterMJWilliamsITMoyerLAJudsonFNMottramK, Incidence and risk factors for acute hepatitis B in the United States, 1982–1998: Implications for vaccination programs. J Infect Dis2002;185:713–9.
3.
Recommendation of the Advisory Committee on Immunization Practices (ACIP): Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep1982; 31(24):317–22,327–8.
4.
JainNYusufHWortleyPMEulerGLWaltonSStokleyS.Factors associated with receiving hepatitis B vaccination among high-risk adults in the United States: An analysis of the National Health Interview Survey, 2000. Fam Med2004;36:480–6.
5.
MastEEWeinbaumCMFioreEAlterMJBellBPFinelliL, A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: Immunization of adults. MMWR Recomm Rep2006; 55(RR-16):1–33.
6.
HepatitisB, Vaccination among high-risk adolescents and adults—San Diego, California, 1998–2001. MMWR Morb Mortal Wkly Rep2002; 51(28):618–21.
7.
HarrisJLJonesTSBuffingtonJ.Hepatitis B vaccination in six STD clinics in the United States committed to integrating viral hepatitis prevention services. Public Health Rep2007; 122(suppl 2):42–7.
8.
SubiadurJHarrisJLRietmeijerCA. Integrating viral hepatitis prevention services into an urban STD clinic: Denver, Colorado. Public Health Rep2007; 122(suppl 2):12–7.
9.
LandryDJForrestJD. Public health departments providing sexually transmitted disease services. Fam Plann Perspect1996; 28:261–6.
10.
MessonnierMMeltzerM.Cost-benefit analysis. In: HaddixAMTeutschSMCorsoPS, editors. Prevention effectiveness: A guide to decision analysis and economic evaluation, 2nd ed.New York: Oxford University Press; 2003. p. 127–55.
11.
CorsoPSHaddixAC. Time effects. In: HaddixAMTeutschSMCorsoPS, editors. Prevention effectiveness: A guide to decision analysis and economic evaluation, 2nd ed.New York: Oxford University Press; 2002. p. 92–102.
12.
SonnenbergFABeckJR. Markov models in medical decision making: A practical guide. Med Decision Making1993; 13:322–38.
13.
ColemanPJMcQuillanGMMoyerLALambertSBMargolisHS. Incidence of hepatitis B virus infection in the United States, 1976 -1994: estimates from the National Health and Nutrition Examination Surveys. J Infect Dis 1998;178:954–9.
14.
McMahonBJAlwardWLHallDBHeywardWLBenderTRFrancisDP, Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis1985; 151:599–603.
15.
EdmundsWJMedleyGFNokesDJHallAJWhittleHC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci1993; 253:197–201.
16.
Department of Health and Human Services (US). National inpatient sample, Healthcare Cost and Utilization Project2003 [cited 2005 Aug 26]. Available from: URL: http://hcupnet.ahrq.gov
17.
FattovichGBrolloLGiustinaGNoventaFPontissoPAlbertiA, Natural history and prognostic factors for chronic hepatitis type B. Gut1991; 32:294–8.
18.
FattovichGRuggeMBrolloLPontissoPNoventaFGuidoM, Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology1986; 6:167–72.
19.
DragosicsBFerenciPHitchmanEDenkH.Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: A clinical and histologic evaluation of 242 cases. Hepatology1987; 7:302–6.
20.
Moreno-OteroRGarcia-MonzonGGarcia-SanchezAGarciaBuey LPajaresJMDi BisceglieAM. Development of cirrhosis after chronic type B hepatitis: A clinicopathologic and follow-up study of 46 HBeAg-positive asymptotic patients. Am J Gastroenterol1991; 86:560–4.
21.
SamplinerREHamiltonFAIseriOATaborEBoitnottJ.The liver histology and frequency of clearance of the hepatitis B surface antigen (HBsAg) in chronic carriers. Am J Med Sci1979; 227:17–22.
22.
McMahonBJHolckPBulkowLSnowballM. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759–68.
23.
AlwardWLMcMahonBJHallDBHeywardWLFrancisDPBenderTR. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis1985; 151:604–9.
24.
YangHILuSNLiawYFYouSLSunCAWangLY, Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med2002; 347:168–74.
25.
BeasleyRPHwangL-Y.Overview on the epidemiology of hepatocellular arcinoma. In: HollingerAMLemonSBMargolisHS, editors. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins; 1991. p. 532–5.
26.
ShermanMPeltekianKMLeeC.Screening for hepatocellular in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology1995; 22:432–8.
27.
AriasE. United States life tables, 2002. Natl Vital Stat Rep 2004 Nov 10;53:1–38.
28.
GunnRAMurrayPJAckersMLHardisonWGMargolisHS. Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic: Rationale for integrating services. Sex Transm Dis2001; 28:166–70.
KimSYBillahKLieuTAWeinsteinMC. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. Am J Prev Med2006; 30:498–506.
31.
HepatitisB, Vaccination of inmates in correctional facilities—Texas, 2000–2002. MMWR Morb Mortal Wkly Rep2004; 53(30):681–3.
32.
BlosteinJClarkPA. Cost-effectiveness of preimmunization hepatitis B screening in high-risk adolescents. Public Health Rep2001; 116:165–8.
33.
AndreFE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med1989; 87(3A):14S–20S.
34.
JilgWDeinhardtF.Results of immunization with a recombinant yeast-derived hepatitis B vaccine. J Infect1986; 13(suppl A):47–51.
35.
HadlerSCFrancisDPMaynardJEThompsonSEJudsonFNEchenbergDF, Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med1986; 315:209–14.
36.
ZimmermanRFinleyCRabinsCMcMahonK. Integrating viral hepatitis prevention into the STD prevention program in Illinois (excluding Chicago), 1999 −2005. Public Health Rep 2007;122(suppl 2):18–23.
37.
MillerMAReddSHadlerSHinmanA.A model to estimate the potential economic benefits of measles eradication for the United States. Vaccine1998; 16:1917–22.
38.
Bureau of Labor Statistics (US). Usual weekly earnings of wage and salary workers: Fourth quarter2003; table 2: Median weekly earnings of full-time wage and salary workers by age, race, Hispanic or Latino ethnicity, and sex, fourth quarter 2003 averages, not seasonally adjusted [press release]; 2004 Jan 16 [cited 2004 Nov 8]. Available from: URL: http://www.bls.gov/news.release/archives/wkyeng_01162004.pdf
Bureau of Labor Statistics (US). Average hourly earnings of production and nonsupervisory workers on private nonfarm payrolls by industry sector and selected industry detail seasonally adjusted [cited 2007 Nov 3]. Available from: URL: http://www.bls.gov/webapps/legacy/cesbtab4.htm
41.
PetittiDB. Meta-analysis, decision analysis, and cost-effectiveness analysis: Methods for quantitative synthesis in medicine. New York: Oxford University Press; 2000.
42.
GilbertLKBulgerJScanlonKFordKBergmire-SweatDWeinbaumC. Integrating hepatitis B prevention into sexually transmitted disease services: U.S. sexually transmitted disease program and clinic trends—1997 and 2001 Sex Transm Dis 2005;32:346–50.
43.
WilsonBCMoyerLSchmidGMastEVoigtRMahoneyF, Hepatitis B vaccination in sexually transmitted disease (STD) clinics: A survey of STD programs. Sex Transm Dis2001; 28:148–52.
44.
BillahKBuffingtonJWeinbaumCMastESubiadurJZimmermanR, Economic implications of hepatitis B vaccination of adults at sexually transmitted disease clinics in the United States. Poster abstract in the proceedings of National STD Prevention Conference; 2004 Mar 8–11; Philadelphia.
45.
KanwalFGralnekIMMartinPDulaisGSFaridMSpiegelBM. Treatment alternatives for chronic hepatitis B virus infection: A cost-effectiveness analysis. Ann Intern Med2005; 142:821–31.
46.
MenziesRMcIntyreP.Vaccine preventable diseases and vaccination policy for indigenous populations. Epidemiol Rev2006; 28:71–80.
